TEVA PHARMACEUTICAL INDUSTRIES LTD

For the period ended Dec 31, 2024. Filed Feb 5, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 5, 2025

TEVA$42.97+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of cash flows

	Year ended December 31,
	2024	2023	2022
Operating activities:
Net income (loss)	$(1,959)	$(615)	$(2,499)
Adjustments to reconcile net income (loss) to net cash provided by operations:
Impairment of goodwill	1,280	700	2,045
Impairment of long-lived assets and assets held for sale	1,275	378	402
Depreciation and amortization	1,059	1,153	1,308
Net change in operating assets and liabilities	(435)	(72)	1,355
Deferred income taxes — net and uncertain tax positions	(634)	(317)	(1,064)
Stock-based compensation	123	121	124
Net loss (gain) from sale of business and long-lived assets	(22)	(41)	10
Other items *	560	61	(91)
Net cash provided by (used in) operating activities	1,247	1,368	1,590
Investing activities:
Beneficial interest collected in exchange for securitized trade receivables	1,291	1,477	1,140
Purchases of property, plant and equipment and intangible assets	(498)	(526)	(548)
Proceeds from sale of business and long lived assets	43	68	68
Purchases of investments and other assets	(71)	(46)	(1)
Proceeds from sale of investments	40	—	4
Acquisitions of businesses, net of cash acquired	(15)	—	(7)
Other investing activities	2	(5)	—
Net cash provided by (used in) investing activities	792	968	656
Financing activities:
Repayment of senior notes and loans and other long term liabilities	(1,641)	(4,152)	(1,369)
Proceeds from senior notes, net of issuance costs	—	2,451	—
Proceeds from short term debt	—	700	—
Repayment of short term debt	—	(700)	—
Purchase of shares from non-controlling interests	(64)	—	—
Dividends paid to non-controlling interests	(78)	—	—
Other financing activities	(8)	(212)	(118)
Net cash provided by (used in) financing activities	(1,791)	(1,913)	(1,487)
Translation adjustment on cash and cash equivalents	(174)	(30)	(123)
Net change in cash, cash equivalents and restricted cash	74	393	636
Balance of cash, cash equivalents and restricted cash at beginning of year	3,227	2,834	2,198
Balance of cash, cash equivalents and restricted cash at end of year	$3,300	$3,227	$2,834
Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:
Cash and cash equivalents	3,300	3,226	2,801
Restricted cash included in other current assets	—	1	33
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	3,300	3,227	2,834

*	Adjustment in the year ended December 31, 2024 mainly relates to an agreement with the Israeli Tax Authorities to settle certain litigation in an amount of $495 million relating to taxes payable for the years 2008 through 2020.

Supplemental cash flow information:

	Year ended December 31,
	2024	2023	2022
Non-cash financing and investing activities:
Beneficial interest obtained in exchange for securitized trade receivables	$1,286	$1,446	$1,189
Dividend declared to non-controlling interests	—	$67	$—
Cash paid during the year for:
Interest	$1,004	$1,078	$948
Income taxes, net of refunds	$471	$298	$543

Net change in operating assets and liabilities:

	Year ended December 31,
	2024	2023	2022
Other current assets	$(1,104)	$(1,525)	$(828)
Trade payables, accrued expenses, employee-related obligations and other liabilities	258	1,588	2,012
Trade receivables net of sales reserves and allowances	245	12	334
Inventories	166	(147)	(163)
	$(435)	$(72)	$1,355

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.